416 results match your criteria: "Spain (V.D.); and Centre of Comparative Medicine and Bioimaging (CMCIB)[Affiliation]"

Safety outcomes of ketamine for treatment-resistant depression in clinical settings and development of the ketamine side effect tool-revised (KSET-R).

Psychiatry Res

December 2024

Black Dog Institute, Sydney, Australia; Discipline of Psychiatry and Mental Health, School of Clinical Medicine, University of New South Wales, Australia; The George Institute for Global Health, Sydney, Australia.

Background: Ketamine and its derivates (e.g. esketamine) are increasingly used in clinical settings for treatment-resistant depression (TRD).

View Article and Find Full Text PDF

In recent years, many population pharmacokinetic (popPK) models have been developed for echinocandins to better understand the pharmacokinetics (PK) of these antifungals. This comprehensive review aimed to summarize popPK models of echinocandins (micafungin, caspofungin, anidulafungin, and rezafungin), by focusing on dosage optimization to maximize the probability of attaining the PK/PD target proposed in special populations. A search in PubMed, Embase, Web of Science, and Scopus, supplemented by the bibliography of relevant articles, was conducted from inception to March 2024, including both observational and prospective trials.

View Article and Find Full Text PDF

Background: In STREAM-1 (Strategic Reperfusion Early After Myocardial Infarction), excess intracranial hemorrhage occurred in patients aged ≥75 years receiving full-dose tenecteplase as part of a pharmaco-invasive strategy, whereas no further intracranial hemorrhage occurred after halving the tenecteplase dose. In STREAM-2 (Second Strategic Reperfusion Early After Myocardial Infarction), half-dose tenecteplase was an effective and safe pharmaco-invasive strategy in older patients with ST-segment-elevation myocardial infarction presenting within <3 hours, compared with primary percutaneous coronary intervention (PCI). We prespecified evaluating the efficacy and safety of a half-dose versus full-dose pharmaco-invasive strategy and compared the half-dose pharmaco-invasive strategy to primary PCI in patients aged ≥75 years.

View Article and Find Full Text PDF

Background: There are no clinical or laboratory markers that can diagnose acute mesenteric ischemia (AMI) accurately. This study aimed to find differences in clinical and laboratory markers between arterial occlusive AMI and other acute abdominal diseases where AMI was initially suspected.

Methods: This was a post hoc study of an international prospective multicenter study where data on patients with suspected AMI were collected.

View Article and Find Full Text PDF

Site-Specific Glyco-Tagging of Native Proteins for the Development of Biologicals.

J Am Chem Soc

December 2024

Chemical Biology and Drug Discovery, Utrecht Institute for Pharmaceutical Sciences, and Bijvoet Center for Biomolecular Research, Utrecht University, Utrecht, CG 3584, The Netherlands.

Glycosylation is an attractive approach to enhance biological properties of pharmaceutical proteins; however, the precise installation of glycans for structure-function studies remains challenging. Here, we describe a chemoenzymatic methodology for glyco-tagging of proteins by peptidoligase catalyzed modification of the -terminus of a protein with a synthetic glycopeptide ester having an -acetyl-glucosamine (GlcNAc) moiety to generate an -GlcNAc modified protein. The GlcNAc moiety can be elaborated into complex glycans by -glycosylation using well-defined sugar oxazolines and mutant forms of endo β--acetylglucosaminidases (ENGases).

View Article and Find Full Text PDF

Prevalence of Progression Independent of Relapse Activity and Relapse-Associated Worsening in Patients With AQP4-IgG-Positive NMOSD.

Neurology

December 2024

From the Department of Neuroscience (P.S., A.V.D.W., P.G.S., Y.C.F., W.Z.Y., C.Z., V.G.J., H.B., M.M.), Central Clinical School, Monash University, Melbourne, Victoria; Department of Neurology (P.S., A.V.D.W., P.G.S., Y.C.F., W.Z.Y., V.G.J., H.B., M.M.), Alfred Health, Melbourne, Victoria, Australia; Department of Neurology (P.S., S.H.), Walton Centre NHS Foundation Trust, Liverpool, United Kingdom; Neuroimmunology Centre (S.S., I.R., T.K.), Department of Neurology, The Royal Melbourne Hospital, Parkville; CORe (S.S., I.R., T.K.), Department of Medicine, University of Melbourne, Victoria; Royal Hobart Hospital (Y.C.F.), Hobart, Tasmania, Australia; Nehme and Therese Tohme Multiple Sclerosis Center (S.J.K.), American University of Beirut Medical Center, Beirut, Lebanon; Department of Neurology (T.C.), Faculty of Medicine, University of Debrecen, Hungary; Department of Neurology (B.W.), Antwerp University Hospital, Edegem; Translational Neurosciences Research Group (B.W.), Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, Belgium; Faculty of Medicine (M.E.), Isfahan University of Medical Sciences; Neurology (M.E.), Dr. Etemadifar MS Institute, Isfahan, Iran; Izmir University of Economics (S.O.), Medical Point Hospital; Multiple Sclerosis Research Association (S.O.), Izmir, Turkey; Department of Neurology and Center of Clinical Neuroscience (P.N., D.H.), First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic; Department of Neurology (A.A.), School of Medicine and Koc University Research Center for Translational Medicine (KUTTAM), Koc University, Istanbul, Turkey; College of Medicine & Health Sciences and Sultan Qaboos University Hospital (A.A.-A.), Sultan Qaboos University, Al-Khodh, Oman; Department of Neuroscience (C.M.R.-T.), Hospital Germans Trias I Pujol, Badalona, Spain; Department of Neurology (G.L.), University Hospital Ghent, Belgium; Department of Medical and Surgical Sciences and Advanced Technologies (F.P.), GF Ingrassia, Catania, Italy; Multiple Sclerosis Unit (F.P.), AOU Policlinico G Rodolico-San Marco, University of Catania; Department of Neuroscience (M.F.), MS Center, Neurology Unit, S. Maria delle Croci Hospital, AUSL Romagna, Ravenna, Italy; Department of Biotechnological and Applied Clinical Sciences (DISCAB) (M.F.), University of L'Aquila, Italy; Department of Neurology (C.B.), Karadeniz Technical University, Medical Faculty, Trabzon, Turkey; Department of Neurology (P.A.M.), Royal Brisbane Hospital; University of Queensland (P.A.M.), Australia; Department of Neurology (R.T.), Haydarpasa Numune Training and Research Hospital, Istanbul, Turkey; Hunter Medical Research Institute (J.L.-S.), Neurology, University of Newcastle; and Hunter New England Health (J.L.-S.), John Hunter Hospital, New South Wales, Australia.

Article Synopsis
  • The study investigated the prevalence of two types of disability progression in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (AQP4-IgG NMOSD): Progression Independent of Relapse Activity (PIRA) and Relapse-Associated Worsening (RAW).
  • It included 181 patients from the MSBase registry, mostly females with an average age of 38.1 years, monitored for an average of 4.5 years, where only 2.2% experienced PIRA and 7.2% experienced RAW.
  • The findings suggest PIRA is rare in AQP4-IgG NMOSD cases, but the study had limitations, such as using
View Article and Find Full Text PDF

Adrenomyeloneuropathy is a progressive neurodegenerative disease caused by pathogenic variants in the gene, resulting in very-long-chain fatty acid (VLCFA) accumulation that leads to dying-back axonopathy. Our candidate gene therapy, SBT101 (AAV9-human [h]), aims to ameliorate pathology by delivering functional copies of h to the spinal cord. Transduced cells produce functional ABCD1 protein, thereby repairing the underlying biochemical defect.

View Article and Find Full Text PDF

Evolution and Impact of Hepatitis A Epidemiology in Europe-Systematic Literature Review of the Last 20 Years.

J Viral Hepat

January 2025

Epidemiology, Biostatistics and Prevention Institute, WHO Collaborating Centre for Travellers' Health, University of Zurich, Zurich, Switzerland.

While globally hepatitis A (hepA) infections occur in 150 million people annually, European high-income countries now have a low endemicity. However, this results in a more susceptible adult population which is prone to severe illness. To determine current epidemiological characteristics, we performed a systematic literature review to assess the severity of hepA disease in the past two decades in 11 European countries (i.

View Article and Find Full Text PDF

Mammalian cell-based production of glycans, glycopeptides and glycomodules.

Nat Commun

November 2024

Copenhagen Center for Glycomics, Departments of Cellular and Molecular Medicine, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark.

Access to defined glycans and glycoconjugates is pivotal for discovery, dissection, and harnessing of a range of biological functions orchestrated by cellular glycosylation processes and the glycome. We previously employed genetic glycoengineering by nuclease-based gene editing to develop sustainable production of designer glycoprotein therapeutics and cell-based glycan arrays that display glycans in their natural context at the cell surface. However, access to human glycans in formats and quantities that allow structural studies of molecular interactions and use of glycans in biomedical applications currently rely on chemical and chemoenzymatic syntheses associated with considerable labor, waste, and costs.

View Article and Find Full Text PDF

This state-of-the-art review aimed to synthesize evidence from various sex-stratified studies on aortic stenosis (AS), focusing on the difference in clinical presentation, anatomical characteristics, pathophysiology, and management of AS. In comparison to men, women with AS are present at later stages, are older, more symptomatic, frailer, and exhibit higher operative risk [Society of Thoracic Surgeons (STS) score]. Women tend to have smaller aortic valve (AV) areas and left ventricular (LV) outflow tract, leading to lower stroke volumes (SVs) than men and have a higher prevalence of paradoxical, low-flow, low-gradient AS.

View Article and Find Full Text PDF

A pathogenic mutation in the ALS/FTD gene VCP induces mitochondrial hypermetabolism by modulating the permeability transition pore.

Acta Neuropathol Commun

October 2024

Laboratory of Neurobiology, Department of Neurosciences, Experimental Neurology and Leuven Brain Institute (LBI), KU Leuven - University of Leuven, Leuven, Belgium.

Article Synopsis
  • Valosin-containing protein (VCP) is linked to amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), and this study investigates how a mutation in VCP affects mitochondrial function using CRISPR/Cas9 in neuroblastoma cells.
  • The mutated cells show enlarged mitochondria with a depolarized membrane potential, leading to increased respiration and heightened activity in the electron transport chain.
  • The findings suggest that VCP mutations may cause mitochondrial hypermetabolism through changes in the permeability transition pore (mPTP), impacting mitochondrial function and contributing to disease progression.
View Article and Find Full Text PDF

Geometric Changes in Mitral Valve Apparatus during Long-term Cardiac Resynchronization Therapy as Assessed with Cardiac CT.

Radiol Cardiothorac Imaging

October 2024

From the Department of Cardiology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, 8200 Aarhus N, Denmark (D.B.F., B.L.N., M.B.K., J.M.J., J.C.N.); Department of Clinical Medicine, Aarhus University, Aarhus N, Denmark (D.B.F., B.L.N., M.B.K., J.C.N.); Medical Diagnostic Center, Silkeborg and Viborg Regional Hospital, Denmark (D.B.F.); Department of Medical Imaging, St Paul's Hospital, Vancouver, Canada (P.B., J.D., K.K., J.L.); University of British Columbia, Vancouver, Canada (P.B., J.L.); Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark (A.S.); Department of Bioengineering, UC San Diego School of Engineering, La Jolla, Calif (E.R.M.); Departments of Radiology and Cardiology, UC San Diego School of Medicine, La Jolla, Calif (E.R.M.); Heart Institute, University Hospital Germans Trias i Pujol, Badalona, Spain (V.D.); and Centre of Comparative Medicine and Bioimaging (CMCIB), Badalona, Spain (V.D.).

Purpose To assess long-term geometric changes of the mitral valve apparatus using cardiac CT in individuals who underwent cardiac resynchronization therapy (CRT). Materials and Methods Participants from a randomized controlled trial with cardiac CT examinations before CRT implantation and at 6 months follow-up (Clinicaltrials.gov identifier NCT01323686) were invited to undergo an additional long-term follow-up cardiac CT examination.

View Article and Find Full Text PDF

microRNAs (miRNAs) are promising biomarkers for many diseases, including multiple sclerosis (MS). The neurofilament light chain (NfL) is a biomarker that can detect axonal damage in different neurological diseases. The objective of this study was to evaluate the association of the expression profile of pre-selected miRNAs and NfL levels with clinical and radiological variables in MS patients.

View Article and Find Full Text PDF

Mantle cell lymphoma (MCL) is genetically characterized by the IG::CCND1 translocation mediated by an aberrant V(D)J rearrangement. CCND1 translocations and overexpression have been identified in occasional aggressive B-cell lymphomas with unusual features for MCL. The mechanism generating CCND1 rearrangements in these tumors and their genomic profile are not known.

View Article and Find Full Text PDF

Intravenous Thrombolysis in Patients With Cervical Artery Dissection: A Secondary Analysis of the STOP-CAD Study.

Neurology

October 2024

From the Department of Neurology (L.S., F. Akpokiere, D.M.M., K.P., V.D., K.B., T.M.B., N.S.K., F. Khan, C.S., N. Mohammadzadeh, E.D.G., K.F., S. Yaghi), Warren Alpert Medical School of Brown University, Providence, RI; Vancouver Stroke Program (T.S.F., L.Z., P.G.), Division of Neurology, University of British Columbia, Vancouver, Canada; Department of Neurology (C.R.L.G.), Atrium Health, Charlotte, NC; Department of Neurology (J. Muppa, N.H.), University of Massachusetts Chan Medical School, Worcester; Department of Neurology (M. Affan, O.U.H.L.), University of Minnesota, Minneapolis; Department of Neurology (M.R.H., K.A., D.J.S., M. Arnold), Inselspital, University Hospital and University of Bern, Switzerland; Department of Neurology (S.S.O., R. Crandall), University of Colorado, Denver; Department of Neurology (E.L.), Weill Cornell Medicine, New York; ; Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suarez (D.L.-M., A. Arauz), Mexico City, Mexico; Service de neurologie (A.N., M.B., E.T.), Université Caen Normandie, CHU Caen Normandie, France; Department of Neurology (J.A.S., J.S.-F., V.B.), Coimbra University, ; Department of Internal Medicine (P.C.-C., M.T.B.), São João University Hospital, Porto, Portugal; Department of Neurology (M.K., D.M.), Corewell Health, Grand Rapids, MI; Department of Neurology (M.K.), Mayo Clinic, Rochester, MN; Department of Neurology (A.R., O.K.), University of Pennsylvania, Philadelphia; Neurology and Neurorehabilitation (J.E.K., S.T.E., C.T.), University Department of Geriatric Medicine FELIX PLATTER, Department of Clinical Research, University of Basel, and University Hospital Basel, Switzerland; Stroke Center (D.A.d.S.), Centro Hospitalar Universitário Lisboa Central, and Institute of Anatomy, Faculdade de Medicina da Universidade de Lisboa; Department of Neurology (M.D.S.); Department of Neuroradiology (S.B.R.), Centro Hospitalar Universitário Lisboa Central, Lisbon, Portugal; Vancouver Stroke Program (S. Mancini), Division of Neurology, University of British Columbia, Vancouver, Canada; Department of Neurology (I.M., R.R.L.), Hadassah-Hebrew University Medical Center, Jerusalem, Israel; Department of Neurology with Experimental Neurology (R.V.R., C.H.N.), Charite Universitätsmedizin-Berlin and Center for Stroke Research, Berlin, and Berlin Institute of Health, Germany; Department of Neurosciences (R. Choi, J. MacDonald), ChristianaCare, Newark, DE; Department of Neurology (R.B.S.), University of California at San Diego; Department of Neurology (X.G.), Loma Linda University, Loma Linda, CA; Department of Neurology (M. Ghannam, M. Almajali, E.A.S.), University of Iowa, Iowa City; Department of Neurosciences (B.R., F.Z.-E., A.P.), Université de Montréal, Canada; Department of Neurology (A.C.F., M.F.B., D.C.), Hospital de Santa Maria, Centro de Estudos Egas Moniz, Faculdade de Medicina, Universidade de Lisboa, Portugal; Neurology and Stroke Unit (M. Romoli, G.D.M., M.L.), Department of Neuroscience, Bufalini Hospital, Cesena, Italy; Department of Neurology (Z.K., K.J.G.), Mayo Clinic, Rochester, MN; Department of Neurology (L.K., J.A.F.), NYU Langone Health, New York; Department of Neurology (J.Y.A., J.A.G.), Washington University, Saint Louis, MO; Neurology Unit, Stroke Unit (M. Zedde, I.G.), Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia; Neuroradiology Unit (R.P.), Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia; Department of Internal Medicine (H.N.), Centro Hospital Universitario do Algarve, Faro, Portugal; Department of Neurology (D.S.L., A.M.), University of California at Los Angeles; Department of Neurology (A.C., B.M.G., R.W.), Duke University, Durham, NC; Department of Neurology (W.K.), University of North Carolina Health Rex, Raleigh; Department of Neurology (S.A.K., M. Anadani), Medical University of South Carolina, Charleston, SC; Department of Neurosurgery (K.P.K.), Medical University of South Carolina, Charleston, SC; Department of Neurology (A.E., L.C., R.C.R., Y.N.A., E.A.M.), University of Cincinnati Medical Center, OH; Department of Neurology (E.B., T.L.T.), University of Alabama at Birmingham; Department of Neurology (M.R.-G., M. Requena), University Hospital Vall d'Hebron, Barcelona, Spain; Department of Neurology (F.G.S.V., J.O.G.), University of Oklahoma; Department of Neurology (V.M.), Einstein-Jefferson Healthcare Network, Philadelphia, PA; Department of Neurology (A.H.), University of Utah, Salt Lake City; Department of Neurology (A.H.); Department of Neurology (S. Sanchez, A.S.Z., Y.K.C., R.S.), Yale New Haven Hospital, New Haven, CT; Department of Neurology (V.Y.V.), All India Institute of Medical Sciences, New Delhi, India; Department of Neurology (S. Yaddanapudi, L.A., A. Browngoehl), Thomas Jefferson University, Philadelphia, PA; Department of Neurology (T.R., R.D., Z.L.), Wake Forest Medical Center, NC; Department of Neurology (M.P., J.E.S.), Cooper University, Camden, NJ; Department of Neurology (S. Mayer, J.Z.W.), Columbia University Medical Center, New York, NY; Department of Neurology (J.P.M., D.K.), Hospital de Egas Moniz, Centro Hospitalar Lisboa Ocidental, Lisbon, Portugal; Department of Neurology (P.K., T.N.N.), Boston Medical Center, MA; Department of Neurology (S.D.A., Z.S., A. Balabhadra, S.P.), Hartford Hospital, CT; Department of Neurology (T.S.), Hospital Moinhos de Vento; Department of Neurology (S.C.M., G.P.M.), Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil; Department of Neurology (Y.D.K.), Yonsei University, Seoul, South Korea; Department of Neurology (B.K., C.E.), University of Tennessee at Memphis; Department of Neurology (S. Lingam, A.Y.Q.), Kansas University Medical Center, Kansas City; Department of Neurology (S.F., A. Alvarado), Western Ontario University, London, Canada; Department of Neurology (F. Khasiyev, G.L.), Saint Louis University, MO; Department of Neurology and Stroke Unit (M.M., V.T.), AOOR Villa Sofia-V. Cervello, Palermo, Italy; First Department of Neurology (A.T., V.T.-P.), National and Kapodistrian University of Athens, Greece; Department of Neurology (M.M.M.-M., V.C.W.), Centro Médico Nacional Siglo XXI IMSS., México City; Department of Neurology (F.I., S.E.E.J.), The Miriam Hospital, Providence, RI; Department of Neurocritical Care (S. Liu, M. Zhou), The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology, Hefei, China; Department of Neurology (M.M.A., F. Ali, M.S.), West Virginia University, WV; Department of Neurology (R.Z.M., T.K.-H.), University of Chicago, IL; Department of Neurology (F.S., J.Z.), Sir Run Run Shaw Hospital of Zhejiang University Medical School, Hangzhou, China; Department of Neurology (D.S., J.S., N. Mongare), Aga Khan University, Nairobi, Kenya; Department of Neurology (A.N.S., R.G., Shayak Sen), Cedars Sinai Medical Center, Los Angeles, CA; Department of Neurology (M. Ghani, M.E.), University of Louisville, KY; and Department of Economics (H.X.), University of California, Santa Barbara.

Article Synopsis
  • Cervical artery dissection (CeAD) is a leading cause of ischemic strokes in young adults, and this study explored the effects of intravenous thrombolysis (IVT) on patients with CeAD and stroke symptoms.
  • Analyzed data from the STOP-CAD study, it found that IVT significantly improved functional independence after 90 days in patients without increasing the risk of symptomatic intracranial hemorrhage.
  • The results suggest that IVT is a beneficial treatment for eligible patients with CeAD, aligning with current medical guidelines on its use.
View Article and Find Full Text PDF

Targeting EGLN2/PHD1 protects motor neurons and normalizes the astrocytic interferon response.

Cell Rep

September 2024

KU Leuven - University of Leuven, Department of Neurosciences, Experimental Neurology and Leuven Brain Institute (LBI), 3000 Leuven, Belgium; VIB, Center for Brain & Disease Research, Laboratory of Neurobiology, 3000 Leuven, Belgium. Electronic address:

Article Synopsis
  • Researchers found that inflammation and energy problems can harm nerve cells in ALS.
  • They discovered that lowering a protein called EGLN2 helped protect these nerve cells in zebrafish and mice.
  • The study showed that EGLN2 is important for controlling inflammation in brain cells of ALS patients.
View Article and Find Full Text PDF

Predictors of Care Home Admission and Survival Rate in Patients With Syndromes Associated With Frontotemporal Lobar Degeneration in Europe.

Neurology

October 2024

From the Department of Clinical and Experimental Sciences (B.B.), University of Brescia; Department of Continuity of Care and Frailty (B.B., A.C.A.), ASST Spedali Civili, Brescia; Medical and Genomic Statistics Unit (B.T., M.G.), Department of Brain and Behavioural Sciences, University of Pavia, Italy; Division of Neurogeriatrics (C.G.), Department NVS, Karolinska Institutet, Solna; Unit for Hereditary Dementia (C.G.), Theme Inflammation and Aging, Karolinska University Hospital-Solna, Stockholm, Sweden; Research Unit of Clinical Medicine (J.K., S.A.-S., A.M.P.), Neurology, University of Oulu; MRC (J.K., A.M.P.), Oulu University Hospital; Neurocenter (J.K.), Neurology, Oulu University Hospital, Finland; Department of Neurology (A.C.L., M.O.), University of Ulm; Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE) (A.C.L.), Ulm, Germany; Cognitive Disorders Unit (F.M., M.B., A.G.), Department of Neurology, Hospital Universitario Donostia; Neuroscience Area (F.M., M.B., A.G.), Biogipuzkoa Health Research Institute, San Sebastian, Spain; Department of Neurology (M.O.), Martin Luther University, University Hospital, Halle (Saale), Germany; MRC Cognition and Brain Sciences Unit (J.B.R., A.G.M., T.R.), Department of Clinical Neurosciences, and Cambridge University Hospitals NHS Trust, University of Cambridge, Cambridge, United Kingdom; Department of Neurology and Alzheimer Center Erasmus MC (H.S., E.V.D.E., J.C.V.S.), Erasmus MC University Medical Center, Rotterdam, the Netherlands; Neurology (E. Solje, P.H.), Institute of Clinical Medicine, University of Eastern Finland; Neurocenter (E. Solje), Neurology, Kuopio University Hospital, Finland; Neurology Clinic (E. Stefanova, G.M.S.), Faculty of Medicine, University Clinical Center, University of Belgrade; UH Alexandrovska (L.D.T., S.M.), Department of Neurology, Medical University Sofia, Bulgaria; Theme Inflammation and Aging (V.J.), Medical Unit Aging Brain, Karolinska University Hospital Huddinge, Solna; Division of Clinical Geriatrics (V.J.), Department NVS, Karolinska Institutet, Huddinge, Sweden; Molecular Markers Laboratory (R.G.), IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia; and Center for Neurodegenerative Diseases and the Aging Brain (M.T.D., C.Z., G.L.), Pia Fondazione Cardinale Giovanni Panico, University of Bari-Aldo Moro, Italy.

Background And Objectives: Data on care home admission and survival rates of patients with syndromes associated with frontotemporal lobar degeneration (FTLD) are limited. However, their estimation is essential to plan trials and assess the efficacy of intervention. Population-based registers provide unique samples for this estimate.

View Article and Find Full Text PDF
Article Synopsis
  • Patients with transposition of the great arteries (TGA) and systemic right ventricle face serious heart-related risks, and researchers sought to determine if specific invasive hemodynamic measures can predict outcomes.
  • The study included 242 adults who underwent cardiac catheterization from 1994 to 2020, analyzing various hemodynamic parameters over an average follow-up period of 11.4 years.
  • Results indicated that a low aortic pulsatility index (<1.5) strongly predicts negative outcomes such as death or the need for heart transplantation, with the cold/wet hemodynamic profile presenting the highest associated risk.
View Article and Find Full Text PDF

Improving outcome measures in late onset Pompe disease: Modified Rasch-Built Pompe-Specific Activity scale.

Eur J Neurol

December 2024

Department of Neurology, Center for Lysosomal and Metabolic Diseases, Erasmus Medical Center, University Medical Center Rotterdam, Rotterdam, the Netherlands.

Article Synopsis
  • - The R-PAct scale is designed to measure how Pompe disease affects daily life, and this study aimed to validate it for use in different languages and countries.
  • - Researchers created German, French, Italian, and Spanish versions of the scale and collected data from Pompe patients in several countries, combining it with existing data for analysis.
  • - Results showed that the modified R-PAct scale is valid and effectively measures two key areas of patient activity, with a minor adjustment made to improve its reliability across diverse populations.
View Article and Find Full Text PDF

Blood DNA methylomic signatures associated with CSF biomarkers of Alzheimer's disease in the EMIF-AD study.

Alzheimers Dement

October 2024

Department of Clinical and Biomedical Sciences, Faculty of Health and Life Sciences, University of Exeter, Exeter, Devon, UK.

Article Synopsis
  • The study examined DNA methylation patterns in blood samples related to 15 key biomarkers of Alzheimer's disease, focusing on neuroinflammation and neurodegeneration effects.
  • Using 885 samples from the EMIF-AD study, researchers identified significant differential methylation connected to CSF levels of YKL-40 and neurofilament light chain (NfL).
  • Findings suggest a link between YKL-40 DNA methylation and genetic variants, with implications for understanding how DNA methylation influences protein levels relevant to Alzheimer's disease.
View Article and Find Full Text PDF

Investigating the 2023 MOGAD Criteria in Children and Adults With MOG-Antibody Positivity Within and Outside Attacks.

Neurology

September 2024

From the Neuroimmunology Program (E.F., G.O.-C., E.M.-H., M.G., E.C., J.M.C.-M., S.L., Y.B., A.S., J.D., M.S., T.A.), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic de Barcelona, Pediatric Neuroimmunology Unit (E.F., V.G.-Á., V.D., T.A.), Neurology Department, Sant Joan de Déu Children's Hospital, and Sant Joan de Déu Private Foundation for Research and Education (IRSJD) Sant Joan de Déu Children's Hospital (E.F.), University of Barcelona; Pediatric Neurology Department (G.O.-C.), Hospital Parc Taulí de Sabadell; Immunology Service (L.N., R.R.G.), Hospital Clinic, and Ophtalmology Service (G.R., C.d.-P.-S.), Sant Joan de Déu Children's Hospital, University of Barcelona; Department of Neurology (J.B.-L.), University Hospital "12 de Octubre"; Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12) (J.B.-L.); Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED) (J.B.-L.); Department of Medicine, Faculty of Medicine (J.B.-L.), Complutense University, Madrid; Neurology Service (C.I.), Hospital Clínico Universitario, Zaragoza; Neurology Service (J.M.G.D.), Hospital General Universitario Gregorio Marañón, Madrid; Neurology Service (C.C.), Hospital Universitario Son Espases, Palma de Mallorca; Neurology Service (A.C.), Hospital de Mataró, Barcelona; Unit of Neuroimmunology and Multiple Sclerosis of Girona (UNIEMTG) (G.Á.B.), Department of Neurology, University Hospital Dr. Josep Trueta of Girona; Neurology Service (I.G.-S.), Hospital Álvaro Cunqueiro, Vigo; Department of Neurology (C.O.-G.), Hospital Clinico San Carlos, IdISSC, Madrid; Departament of Medicine (C.O.-G.), Medicine Faculty, Universidad Complutense de Madrid (UCM); Neurology Service (M.R.), Hospital Parc Taulí, Sabadell, Barcelona; Multiple Sclerosis CSUR and Clinical Neuroimmunology Unit (J.M.-P., J.E.M.-L.), Neurology Department, Hospital Clínico Universitario Virgen de la Arrixaca (IMIB-Arrixaca), Clinical Neuroimmunology and Multiple Sclerosis Cathedra, UCAM, Universidad Católica San Antonio de Murcia; Neurology Service (L.B.C.), Hospital Universitario Fundación Alcorcón, Madrid; Neurology Service (J.M.-M.), Hospital Universitario Miguel Servet, Zaragoza; Neurology Service (M.P., J.G.), Complejo Hospitalario Universitario de Albacete; Neurology Service (R.V.-G.), Hospital Universitario JM Morales Meseguer, Internal Medicine Department, Universidad de Murcia, Spain; Department of Neurology (J.D.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; and Catalan Institution for Research and Advanced Studies (ICREA) (J.D.), Barcelona, Spain.

Background And Objectives: The 2023 criteria for myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) perform well in adults but have not been assessed in children.

Methods: This prospective observational nationwide study includes children and adults with demyelinating syndromes or encephalitis, whose serum or CSF was found MOG-immunoglobulin G (IgG) positive at Institut d'Investigacions Biomèdiques August Pi i Sunyer-Hospital Clínic of Barcelona (Spain). Exclusion criteria were lack of clinical information and follow-up <1 year, and serum unavailable for antibody testing.

View Article and Find Full Text PDF

We compared transplantation (HSCT) outcomes in AML patients undergoing HSCT with post-transplant cyclophosphamide (PTCy) in first complete remission from 1065 young (<35 years) haploidentical (Haplo) donors (yHaplo) vs. 147 old (≥35 years) mismatched unrelated donors (oMMUD) (first comparison) and from 271 young (<35 years) MMUD (yMMUD) vs. 1315 old (≥35 years) Haplo donors (oHaplo) (second comparison).

View Article and Find Full Text PDF
Article Synopsis
  • A study was conducted to evaluate the effectiveness of the Womed Leaf, a degradable polymer film, for treating moderate to severe intrauterine adhesions (IUA) in women undergoing hysteroscopic surgery.
  • The PREG-2 trial was a multicenter, double-blind, randomized controlled trial, involving 160 women who were divided into two groups: one received the Womed Leaf after surgery while the other did not.
  • Results showed that the Womed Leaf significantly improved the reduction of IUAs compared to the control group, with a higher percentage of women showing no adhesions and no serious adverse events related to the device, confirming its safety and effectiveness.
View Article and Find Full Text PDF